Bayer gets go-ahead for Huntington’s Disease gene therapy trial
Drug Discovery World
AUGUST 23, 2022
A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France. . In 2019, BV-101 was granted orphan drug designation in the European Union. . There are currently no approved disease modifying therapies for Huntington’s Disease.
Let's personalize your content